TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Modified Overt Aggression Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression - Improvement Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep apnea measured by polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Nasal Symptom Score Over Days 1-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With HI Antibody Titer Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxygen properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device-related combined endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improved gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eyes With Epithelial Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eyes With Stromal Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eyes With Corneal Vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neoadjuvant therapy toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Lactic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal B-type natriuretic peptide (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peri-implant tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of telerehabilitation technologies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: compliance with mood rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of related Adverse Events (AEs) to rVIIa-FP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects who develop inhibitors against Factor VII (FVII)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects who develop antibodies against rVIIa-FP
Endpoint domain: Adverse events/effects
Primary endpoint: Food craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment-related grade 3-5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Horizontal position stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate of brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Asymptomatic Bacteriuria Treated With Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Urinary Tract Infection Treated With Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Differences in area under the curve in TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences in area under the curve in Prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences in area under the curve in LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences in area under the curve in FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences in area under the curve in Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Type 2 Diabetes Mellitus control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete canine overbite return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent late luminal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: steady state pharmacokinetics of VPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood loss in millilitres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of study subjects who achieve adequate adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: consumption of fruits and vegetables, fat, and sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adherence to CDC-ACSM recommendations for physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver enzyme levels (ASAT, ALAT, γ-GT, AP, LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood clotting factor parameters (INR, APTT, PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Electrolyte levels (Na, K, Cl, Mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Increase in Insulin-stimulated Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Final Histopathologic NAC Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Inhibitory Antibodies to Factor VIII (FVIII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Annualized Bleed Rate (ABR) - Spontaneous Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced IAD Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants With IAD Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in PASS Asthma Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in haemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hearing level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otological status of middle ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking physical activity measured by daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Rate (CR) at 1 Year of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Cmax for PF 04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for PF-04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relevant parenchymatous brain injury on postoperative MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of children that are considered 'too unstable for postoperative MRI'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of Non-Small Cell Lung Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean decrease in diurnal intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the State-Trait Anxiety Inventory Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events (nature, incidence and severity)
Endpoint domain: Adverse events/effects
Primary endpoint: Morning plasma cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACTH challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total sales of beverages
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in daily average nausea severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anti-thyroid peroxidase levels (anti-TPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroglobulin levels (TgAb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of premature withdrawals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Serum PGE2 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Esophageal Tissue PGE2 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of young women identified and recruited as index recruiters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of index recruiters who recruit two or more female friendship network members
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preliminary estimate of HIV infection prevalence among friendship networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in hepatic insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total number of analgesic requests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Right ventricle (RV) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absorption of Lorazepam, Diphenyhydramine, Haloperidol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Retinal Arteriolar Diameter (CRAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Retinal Arteriolar Diameter (CRVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in arteriolar-venular ratio (AVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Flicker-Induced Venular Dilation (vFID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Flicker-Induced Venular Dilation (aFID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUC of ASC41
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ASC41
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Berg balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory miRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of AI System during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peripheral blood B-cell phenotype changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Differences in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity of EBV and methylation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition and nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: toxicity of the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Numeric Rating Scale (NRS) pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean four-week rate of occurrence of new gadolinium enhancing MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Major Bleeding Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Platelet Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ottawa scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of implant placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower of serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-hour mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uptake of HIV Self-testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Polyps regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline PRWE at 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline PRWE between 0 weeks and 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants exceeding a PRWE change of plus 14 between baseline and 9 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants exceeding a PRWE change of plus 14 between baseline and 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Low-dose Whole Brain RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in participants break fall competence/skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participants' fall efficacy after 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Compliance to diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in adherence to therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in tolerability to the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of Immunity to Collagen Type-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in average ambulatory systolic blood pressure over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum low density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of forced expiratory volume in the first second to forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality Adjusted Life gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in uterine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change in EQ-5D Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in EQ-VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change from baseline in percent diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alteration of oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alteration of pCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants Considered Responders on Clinical Global Impressions Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with identified mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak lactate/pyruvate ratio in brain tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak lactate/pyruvate ratio in (13C) pyruvate scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety assessed by unsolicited local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody response to each of the vaccine´s strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Anxiety Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who accepted invitation to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of people with CF who are randomised into the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Suture material complications
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Success based on change in Investigator's Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal volume post-donation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney function post-donation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Transition to schizophrenia
Endpoint domain: Mortality/survival
Primary endpoint: Low birth weight babies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Anti Tumor Necrosis Factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUCinf (AUC extrapolated to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-432h (AUC from the time of dosing to 432 hours post-dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of cellular markers in the dendritic cells (DCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viability of the dendritic cells (DCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokines production by the dendritic cells (DCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Injection Site or Systemic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of shoulder calcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Size of shoulder calcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants with a Major Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with a Clinically Relevant Non-major Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Deaths Reported
Endpoint domain: Mortality/survival
Primary endpoint: Grip Force Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Pain Intensity Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Life Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thickness of scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Urine NGAL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of subjects with small bowel mucosal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cost of knee OA treatment including cost of side effect related to OA treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the curve (AUC) Lequesne index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-hour glycemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Good Neurologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Solicited Adverse Events With Each Vaccination by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Unsolicited Adverse Events at Specified Grades
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With the Occurrence of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Chicago Bowel Preparation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma levels of antioxidant enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Efficacy (bidirectional cavotricuspid isthmus block)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes